David Tait, Founder & Managing Director at Redmill Advance, Calls on Firms to Rethink How Adviser Competence Is Measured01/10/2026
Donald Trump Oil Stock Investments Gained Up to $4.4 Million While He Was Making Wartime Decisions About Iran01/10/2026
Pfizer’s tilrekimig hits Phase 2 goal, moves to Phase 3 trialsBy Martin Holloway01/10/2026 Pfizer’s tilrekimig Phase 2 atopic dermatitis trial hit its primary endpoint, with the drug now advancing into Phase 3 studies in two indications.
David Tait, Founder & Managing Director at Redmill Advance, Calls on Firms to Rethink How Adviser Competence Is Measured01/10/2026
